A follow-on study of high dose levels of entolimod in patients with advanced cancers in Russia.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Apr 2015 Status changed from not yet recruiting to recruiting based on a Cleveland BioLabs media release.
27 Apr 2015 As per a Cleveland BioLabs media release, this trial will be supported by a part of a $1.2 million Breast Cancer Research Program Breakthrough Award to the Roswell Park Cancer Institute by the Department of Defence Congressionally Directed Medical Research Program.
10 Feb 2015 According to Cleveland Biolabs Inc media release, the company has initiated a follow-on study in Moscow, Russia, which is financially supported by the Ministry of Industry and Trade of the Russian Federation.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com